CSTL
Castle Biosciences·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 4
Bearish signal 2
Consensus Rating "Strong Buy"
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
Revenue Beats Expectation
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About CSTL
Castle Biosciences, Inc.
A company that develops and commercializes diagnostic and prognostic tests for dermatologic cancers
Biological Technology
09/12/2007
07/25/2019
NASDAQ Stock Exchange
761
12-31
Common stock
505 S. Friendswood Drive, Suite 401, Friendswood, Texas 77546
--
Castle Biosciences, Inc., was incorporated in Delaware on September 12, 2007. The company is a commercial-stage dermatological cancer company dedicated to providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions.
Earnings Call
Q1/2025
Estimate EPS-0.07
Actual EPS-0.2
Estimate Revenue80.38M
Actual Revenue88.00M
Castle Biosciences Q1 2025: Key Contradictions in Melanoma Strategy, Reimbursement, and Acquisitions
May 06,2025 07:34
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-0.5
Actual EPS0.15
Estimate Revenue71.41M
Actual Revenue86.19M
Castle Biosciences Q2 2025: Contradictions Unveiled in Reimbursement Strategies and FDA Approval Timelines
Aug 04,2025 10:51
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-0.51
Actual EPS-0.02
Estimate Revenue71.14M
Actual Revenue83.00M
Castle Biosciences' Q3 2025 Earnings Call: Contradictions Emerge on SCC Reimbursement and Volume, Melanoma Growth, and Sales Force Allocation
Nov 04,2025 09:29
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
CSTL has released its 2025 Q3 earnings. EPS was reported at -0.02, versus the expected -0.51, beating expectations. The chart below visualizes how CSTL has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CSTL has released its 2025 Q3 earnings report, with revenue of 83.04M, reflecting a YoY change of -3.19%, and net profit of -501.00K, showing a YoY change of -122.08%. The Sankey diagram below clearly presents CSTL's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
